Sorrento Publishes Positive Initial Results of SOFUSA® Lymphatic Drug Delivery System in a Phase 1b Rheumatoid Arthritis Study Using Enbrel

SAN DIEGO, Aug. 23, 2021 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today released a patient case report on the lymphatic delivery of Enbrel using the Sofusa Lymphatic Delivery System (SOFUSA), which has been submitted for preprint as CASE REPORT: Lymphatic delivery of Enbrel® using The Sofusa® Lymphatic Delivery System (SOFUSA) achieves improvement in rheumatoid arthritis disease activity measures in a patient non-responsive to Enbrel subcutaneous injections (

Click here to view original post